Cargando…

APE1/Ref-1 – One Target with Multiple Indications: Emerging Aspects and New Directions

In the realm of DNA repair, base excision repair (BER) protein, APE1/Ref-1 (Apurinic/Apyrimidinic Endonuclease 1/Redox Effector - 1, also called APE1) has been studied for decades. However, over the past decade, APE1 has been established as a key player in reduction-oxidation (redox) signaling. In t...

Descripción completa

Detalles Bibliográficos
Autores principales: Mijit, Mahmut, Caston, Rachel, Gampala, Silpa, Fishel, Melissa L., Fehrenbacher, Jill, Kelley, Mark R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457357/
https://www.ncbi.nlm.nih.gov/pubmed/34557865
_version_ 1784571072565215232
author Mijit, Mahmut
Caston, Rachel
Gampala, Silpa
Fishel, Melissa L.
Fehrenbacher, Jill
Kelley, Mark R.
author_facet Mijit, Mahmut
Caston, Rachel
Gampala, Silpa
Fishel, Melissa L.
Fehrenbacher, Jill
Kelley, Mark R.
author_sort Mijit, Mahmut
collection PubMed
description In the realm of DNA repair, base excision repair (BER) protein, APE1/Ref-1 (Apurinic/Apyrimidinic Endonuclease 1/Redox Effector - 1, also called APE1) has been studied for decades. However, over the past decade, APE1 has been established as a key player in reduction-oxidation (redox) signaling. In the review by Caston et al. (The multifunctional APE1 DNA repair-redox signaling protein as a drug target in human disease), multiple roles of APE1 in cancer and other diseases are summarized. In this Review, we aim to expand on the contributions of APE1 to various diseases and its effect on disease progression. In the scope of cancer, more recent roles for APE1 have been identified in cancer cell metabolism, as well as chemotherapy-induced peripheral neuropathy (CIPN) and inflammation. Outside of cancer, APE1 signaling may be a critical factor in inflammatory bowel disease (IBD) and is also an emergent area of investigation in retinal ocular diseases. The ability of APE1 to regulate multiple transcription factors (TFs) and therefore multiple pathways that have implications outside of cancer, makes it a particularly unique and enticing target. We discuss APE1 redox inhibitors as a means of studying and potentially combating these diseases. Lastly, we examine the role of APE1 in RNA metabolism. Overall, this article builds on our previous review to elaborate on the roles and conceivable regulation of important pathways by APE1 in multiple diseases.
format Online
Article
Text
id pubmed-8457357
institution National Center for Biotechnology Information
language English
publishDate 2021
record_format MEDLINE/PubMed
spelling pubmed-84573572021-09-22 APE1/Ref-1 – One Target with Multiple Indications: Emerging Aspects and New Directions Mijit, Mahmut Caston, Rachel Gampala, Silpa Fishel, Melissa L. Fehrenbacher, Jill Kelley, Mark R. J Cell Signal Article In the realm of DNA repair, base excision repair (BER) protein, APE1/Ref-1 (Apurinic/Apyrimidinic Endonuclease 1/Redox Effector - 1, also called APE1) has been studied for decades. However, over the past decade, APE1 has been established as a key player in reduction-oxidation (redox) signaling. In the review by Caston et al. (The multifunctional APE1 DNA repair-redox signaling protein as a drug target in human disease), multiple roles of APE1 in cancer and other diseases are summarized. In this Review, we aim to expand on the contributions of APE1 to various diseases and its effect on disease progression. In the scope of cancer, more recent roles for APE1 have been identified in cancer cell metabolism, as well as chemotherapy-induced peripheral neuropathy (CIPN) and inflammation. Outside of cancer, APE1 signaling may be a critical factor in inflammatory bowel disease (IBD) and is also an emergent area of investigation in retinal ocular diseases. The ability of APE1 to regulate multiple transcription factors (TFs) and therefore multiple pathways that have implications outside of cancer, makes it a particularly unique and enticing target. We discuss APE1 redox inhibitors as a means of studying and potentially combating these diseases. Lastly, we examine the role of APE1 in RNA metabolism. Overall, this article builds on our previous review to elaborate on the roles and conceivable regulation of important pathways by APE1 in multiple diseases. 2021 /pmc/articles/PMC8457357/ /pubmed/34557865 Text en https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Article
Mijit, Mahmut
Caston, Rachel
Gampala, Silpa
Fishel, Melissa L.
Fehrenbacher, Jill
Kelley, Mark R.
APE1/Ref-1 – One Target with Multiple Indications: Emerging Aspects and New Directions
title APE1/Ref-1 – One Target with Multiple Indications: Emerging Aspects and New Directions
title_full APE1/Ref-1 – One Target with Multiple Indications: Emerging Aspects and New Directions
title_fullStr APE1/Ref-1 – One Target with Multiple Indications: Emerging Aspects and New Directions
title_full_unstemmed APE1/Ref-1 – One Target with Multiple Indications: Emerging Aspects and New Directions
title_short APE1/Ref-1 – One Target with Multiple Indications: Emerging Aspects and New Directions
title_sort ape1/ref-1 – one target with multiple indications: emerging aspects and new directions
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457357/
https://www.ncbi.nlm.nih.gov/pubmed/34557865
work_keys_str_mv AT mijitmahmut ape1ref1onetargetwithmultipleindicationsemergingaspectsandnewdirections
AT castonrachel ape1ref1onetargetwithmultipleindicationsemergingaspectsandnewdirections
AT gampalasilpa ape1ref1onetargetwithmultipleindicationsemergingaspectsandnewdirections
AT fishelmelissal ape1ref1onetargetwithmultipleindicationsemergingaspectsandnewdirections
AT fehrenbacherjill ape1ref1onetargetwithmultipleindicationsemergingaspectsandnewdirections
AT kelleymarkr ape1ref1onetargetwithmultipleindicationsemergingaspectsandnewdirections